Dr Krishna M Ella, Chairman and Managing Director of Bharat Biotech on June 18 (local time) said that the clinical phase III trials of the COVID-19 nasal vaccine have been completed and the company will submit its data with Drugs Controller General of India (DCGI) next month. “We’ve completed a clinical trial, data analysis is going on. We’ll submit the data to regulatory agency. If everything is okay, we’ll get permission to launch and it will be world’s first clinically proven nasal COVID-19 vaccine,” said Dr Krishna M Ella. On the booster dose of COVID-19, Krishna said that those who had taken the second dose must take the booster dose.